Dr. Reddy's launches generic version of antidepressant Wellbutrin in U.S.

• Dr. Reddy's Laboratories' (RDY +2.1%) U.S. commercial launch of its generic version of GlaxoSmithKline's (GSK +3%) antidepressant Wellbutrin SR (bupropion HCl) Sustained-Release Tablets is underway. The company will market 100 mg, 150 mg and 200 mg dosages. The total U.S. market (branded and generic) is ~$110M a year.